Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

Rhea-AI Summary

Madrigal Pharmaceuticals (NASDAQ:MDGL) granted inducement equity awards on November 1, 2025 to 18 new non-executive employees under its 2025 Inducement Plan.

The board’s independent Compensation Committee approved the awards in accordance with Nasdaq Listing Rule 5635(c)(4). In aggregate the new hires received 7,301 time-based restricted stock units (RSUs), which vest in four equal annual installments on each of the first through fourth anniversaries of the grant date, subject to continued employment.

News Market Reaction

+0.14%

1 alert

+0.14% News Effect

On the day this news was published, MDGL gained 0.14%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

CONSHOHOCKEN, Pa., Nov. 06, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), today announced that it granted equity awards on November 1, 2025 to 18 new non-executive employees as equity inducement awards under the terms of Madrigal’s 2025 Inducement Plan. The equity awards were approved by Madrigal’s independent Compensation Committee in accordance with Nasdaq Listing Rule 5635(c)(4).

The equity awards were granted as inducement material to employees’ acceptance of employment with the company. The new employees received, in the aggregate, 7,301 time-based restricted stock units. All restricted stock units granted vest in four equal installments on each of the first through fourth anniversaries of the grant date. The vesting of all awards described above shall be subject to each such employee’s continued employment as of the applicable vesting date.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL) is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a liver disease with high unmet medical need. Madrigal’s medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed THR-β agonist designed to target key underlying causes of MASH. Rezdiffra is the first and only medication approved by both the FDA and European Commission for the treatment of MASH with moderate to advanced fibrosis (F2 to F3). An ongoing Phase 3 outcomes trial is evaluating Rezdiffra for the treatment of compensated MASH cirrhosis (F4c). For more information, visit www.madrigalpharma.com.

Investor Contact
Tina Ventura, IR@madrigalpharma.com

Media Contact
Christopher Frates, media@madrigalpharma.com

FAQ

What did Madrigal (MDGL) announce on November 6, 2025 about employee equity awards?

Madrigal said it granted inducement RSUs on Nov 1, 2025 to 18 new non-executive employees totaling 7,301 RSUs.

How do the 7,301 RSUs granted by MDGL vest and when do they begin vesting?

The RSUs vest in four equal installments on each of the first through fourth anniversaries of the Nov 1, 2025 grant date, subject to continued employment.

Were Madrigal’s inducement awards approved under Nasdaq rules for MDGL?

Yes. The awards were approved by the independent Compensation Committee under Nasdaq Listing Rule 5635(c)(4).

How many employees received inducement awards from Madrigal (MDGL)?

18 new non-executive employees received inducement equity awards.

Do the MDGL RSU awards require continued employment to vest?

Yes. Vesting of all awards is subject to each employee’s continued employment as of each applicable vesting date.

Are the inducement awards part of Madrigal’s 2025 Inducement Plan for MDGL?

Yes. The equity awards were granted under Madrigal’s 2025 Inducement Plan as inducement material to employees’ acceptance of employment.